Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy

Cardiovascular Research

Volumn 57, Issue 3, 2003, Pages 704-714

  Dash, Rajesh ^a   Schmidt, Albrecht G ^b   Pathak, Anand ^a   Gerst, Michael J ^a   Biniakiewicz, Danuta ^c   Kadambi, Vivek J ^d   Hoit, Brian D ^e   Abraham, William T ^f   Kranias, Evangelia G ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Adrenergic (ant)agonists; Contractile function; Gender; Hypertrophy; Second messengers

Indexed keywords

ESTRADIOL; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; NORADRENALIN; PHOSPHOLAMBAN; SYNAPTOPHYSIN;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HEART DILATATION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; IN VITRO STUDY; MALE; MOLECULAR BIOLOGY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TRANSGENIC MOUSE;

ANIMALS; BLOOD PRESSURE; CALCIUM-BINDING PROTEINS; CALCIUM-TRANSPORTING ATPASES; CELLS, CULTURED; ESTRADIOL; FEMALE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE CELLS; NOREPINEPHRINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SEX FACTORS; SIGNAL TRANSDUCTION; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0344211434     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00772-1     Document Type: Article

References (38)

1. Laycock S.K., McMurray J., Kane K.A., et al. Effects of chronic norepinephrine administration on cardiac function in rats. J Cardiovasc Pharmacol. 26:1995;584-589.
2. Kudej R.K., Iwase M., Uechi M., et al. Effects of chronic beta-adrenergic receptor stimulation in mice. J Mol Cell Cardiol. 29:1997;2735-2746.
3. Yamazaki T., Komuro I., Zou Y., et al. Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors. Circulation. 95:1997;1260-1268.
4. Zechner D., Thuerauf D.J., Hanford D.S., et al. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol. 139:1997;115-127.
5. Liao P., Wang S.Q., Wang S., et al. p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res. 90:2002;190-196.
6. Camps M., Nichols A., Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 14:2000;6-16.
7. Franklin C.C., Kraft A.S. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem. 272:1997;16917-16923.
8. Bueno O.F., De Windt L.J., Lim H.W., et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res. 88:2001;88-96.
9. Rapacciuolo A., Esposito G., Caron K., et al. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol. 38:2001;876-882.
10. Nuedling S., Kahlert S., Loebbert K., et al. Differential effects of 17beta-estradiol on mitogen-activated protein kinase pathways in rat cardiomyocytes. FEBS Lett. 454:1999;271-276.
11. van Eickels M., Grohe C., Cleutjens J.P., et al. 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation. 104:2001;1419-1423.
12. Dash R., Kadambi V., Schmidt A.G., et al. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation. 103:2001;889-896.
13. Kadambi V.J., Ponniah S., Harrer J.M., et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest. 97:1996;533-539.
14. Hoit B.D., Khoury S.F., Kranias E.G., et al. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res. 77:1995;632-637.
15. Kim H.W., Steenaart N.A., Ferguson D.G., et al. Functional reconstitution of the cardiac sarcoplasmic reticulum Ca2(+)-ATPase with phospholamban in phospholipid vesicles. J Biol Chem. 265:1990;1702-1709.
16. Brondello J.M., Pouyssegur J., McKenzie F.R. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science. 286:1999;2514-2517.
17. Lorell B.H., Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 102:2000;470-479.
18. Zheng M., Zhang S.J., Zhu W.Z., et al. Beta 2-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by Gi or beta gamma in adult mouse cardiomyocytes. J Biol Chem. 275:2000;40635-40640.
19. Molkentin J.D., Lu J.R., Antos C.L., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228.
20. Morgan J.P. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med. 325:1991;625-632.
21. Adams K.F. Jr., Sueta C.A., Gheorghiade M., et al. Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation. 99:1999;1816-1821.
22. Aurigemma G.P., Silver K.H., McLaughlin M., et al. Impact of chamber geometry and gender on left ventricular systolic function in patients >60 years of age with aortic stenosis. Am J Cardiol. 74:1994;794-798.
23. Douglas P.S., Otto C.M., Mickel M.C., et al. Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. NHLBI Balloon Valvuloplasty Registry. Br Heart J. 73:1995;548-554.
24. Carroll J.D., Carroll E.P., Feldman T., et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation. 86:1992;1099-1107.
25. Douglas P.S., Katz S.E., Weinberg E.O., et al. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol. 32:1998;1118-1125.
26. Weinberg E.O., Thienelt C.D., Katz S.E., et al. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol. 34:1999;264-273.
27. Bristow M.R. Why does the myocardium fail? Insights from basic science. Lancet. 352:(Suppl 1):1998;SI8-14.
28. Liao Y., Cooper R.S., Mensah G.A., et al. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation. 92:1995;805-810.
29. Bellino F.L. Nonprimate animal models of menopause: workshop report. Menopause. 7:2000;14-24.
30. Krepinsky J., Ingram A.J., James L., et al. 17beta-Estradiol modulates mechanical strain-induced MAPK activation in mesangial cells. J Biol Chem. 277:2002;9387-9394.
31. Blanco-Aparicio C., Torres J., Pulido R. A novel regulatory mechanism of MAP kinases activation and nuclear translocation mediated by PKA and the PTP-SL tyrosine phosphatase. J Cell Biol. 147:1999;1129-1136.
32. Fischer M., Baessler A., Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 53:2002;672-677.
33. Roesch D.M., Tian Y., Zheng W., et al. Estradiol attenuates angiotensin-induced aldosterone secretion in ovariectomized rats. Endocrinology. 141:2000;4629-4636.
34. Pelzer T., de Jager T., Muck J., et al. Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition. J Hypertens. 20:2002;1001-1006.
35. Lai L.P., Raju V.S., Delehanty J.M., et al. Altered sarcoplasmic reticulum Ca2+ ATPase gene expression in congestive heart failure: effect of chronic norepinephrine infusion. J Mol Cell Cardiol. 30:1998;175-185.
36. Chu S., Kranias E.G. A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists. J Biol Chem. 275:(49):2000;38938-38943.
37. DiPaola N.R., Sweet W.E., Stull L.B., et al. Beta-adrenergic receptors and calcium cycling proteins in non-failing, hypertrophied and failing human hearts: transition from hypertrophy to failure. J Mol Cell Cardiol. 33:2001;1283-1295.
38. Meerson F.Z. The failing heart. Katz A.M. Adaptation and deadaptation. 1983;Raven Press, New York.